Article info
PDFClinical science
Extended reports
Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia
- Correspondence to: Dr A H Rogers New England Eye Center, 750 Washington Street, Box 450, Boston, MA 02111, USA; arogers1{at}tufts-nemc.org
Citation
Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia
Publication history
- Accepted July 2, 2006
- First published July 26, 2006.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 British Journal of Ophthalmology